Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 1/20 | 0.47 |
| ▸ | PTPN7 | P35236 | 6/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 6/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.43 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.41 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3637053 | 0.89 | NR3C2 (0.49) | NR3C2PTPN7DUSP3KIF11USP28 | |
| SCHEMBL79124 | 0.86 | KIF11 (0.56) | NR3C2KIF11FFAR4GPR84P2RX7 | |
| SCHEMBL297428 | 0.84 | NR3C2 (0.48) | NR3C2PTPN7DUSP3KIF11AR | |
| SCHEMBL3532064 | 0.84 | GLA (0.42) | KIF11FFAR4GPR84 | |
| SCHEMBL78124 | 0.82 | NR3C2 (0.44) | NR3C2PTPN7DUSP3KIF11USP28 | |
| SCHEMBL10299813 | 0.81 | KIF11 (0.58) | NR3C2PTPN7DUSP3KIF11USP28 | |
| SCHEMBL29875866 | 0.81 | KIF11 (0.58) | NR3C2PTPN7DUSP3KIF11USP28 | |
| SCHEMBL93061 | 0.81 | KIF11 (0.58) | NR3C2PTPN7DUSP3KIF11USP28 | |
| SCHEMBL8443136 | 0.81 | GPR84 (0.58) | GPR84 | |
| SCHEMBL28292529 | 0.80 | CYP1A2 (0.50) | NR3C2PTPN7DUSP3FFAR4EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110105514-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-05 | — | — | US | disclosed |
| EP-2307417-A2 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2011-04-13 | — | — | EP | disclosed |
| CN-101781162-A | Method for preparing trifluoromethyl styrene compound | SHANGHAI CHEMEXPLORER CO LTD | 2010-07-21 | — | — | CN | disclosed |
| CN-101781161-A | Method for preparing trifluoromethyl styrene compound | SHANGHAI CHEMEXPLORER CO LTD | 2010-07-21 | — | — | CN | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-2168944-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009156951-A2 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105514-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | HCRTR1, HCRTR2, NPY5R | NR3C2 202/4885PTPN7 1575/4885DUSP3 4386/4885 |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HLA-B, HLA-A, HLA-C | NR3C2 128/4885PTPN7 161/4885DUSP3 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.